Clinical Trial Update: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing obinutuzumab plus chemotherapy vs rituximab plus chemotherapy in untreated advanced indolent non-Hodgkin's lymphoma; results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2017-06-07